New Immuno-oncology Targets and Resistance Mechanisms
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-022-01005-8.pdf
Reference118 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin [Internet]. 2021 May 1 [cited 2021 Sep 23];71(3):209–49. https://doi.org/10.3322/caac.21660.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: Cancer J Clin [Internet]. 2021 Jan 1 [cited 2021 Sep 23];71(1):7–33. https://doi.org/10.3322/caac.21654.
3. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med [Internet]. 2020 Aug 13 [cited 2022 Mar 24];383(7):640–9. https://doi.org/10.1056/NEJMoa1916623.
4. Alexander M, Kim SY, Cheng H. Update 2020: Management of non-small cell lung cancer. Lung [Internet]. 2020 Dec 1 [cited 2022 May 4];198(6):897–907. https://doi.org/10.1007/s00408-020-00407-5.
5. Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet [Internet]. 2021 Feb 13 [cited 2022 Apr 23];397(10274):592–604 Available from: https://pubmed.ncbi.nlm.nih.gov/33581821/.
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties;Cancers;2024-08-26
2. Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition;Small;2024-06-10
3. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?;Pharmacological Research;2024-05
4. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09
5. Modern cancer therapy: cryoablation meets immune checkpoint blockade;Frontiers in Oncology;2024-02-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3